Jean-Luc Harousseau

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Phenomena

Recurrence

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Cahu Xavier; Rialland Fanny; Touzeau Cyrille; Chevallier Patrice; Guillaume Thierry; Delaunay Jacques; Ayari Sameh; Dubruille Viviane; Le Gouill Steven; Mahe Beatrice; Gastinne Thomas; Blin Nicolas; Saulquin Beatrice; Harousseau Jean-Luc; Moreau Philippe; Mohty Mohamad
Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.
Vogl Dan T; Stadtmauer Edward A; Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Facon Thierry; Harousseau Jean-Luc; Boral Anthony; Neuwirth Rachel; Anderson Kenneth C
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Chevallier P; Labopin M; Nagler A; Ljungman P; Verdonck L F; Volin L; Zander A R; Finke J; Socie G; Cordonnier C; Harousseau J-L; Mohty M; Rocha V;
Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jean-Luc Harousseau (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Cahu Xavier; Rialland Fanny; Touzeau Cyrille; Chevallier Patrice; Guillaume Thierry; Delaunay Jacques; Ayari Sameh; Dubruille Viviane; Le Gouill Steven; Mahe Beatrice; Gastinne Thomas; Blin Nicolas; Saulquin Beatrice; Harousseau Jean-Luc; Moreau Philippe; Mohty Mohamad
Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(12):1531-7.
2009: Vogl Dan T; Stadtmauer Edward A; Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Facon Thierry; Harousseau Jean-Luc; Boral Anthony; Neuwirth Rachel; Anderson Kenneth C
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
British journal of haematology 2009;147(4):531-4.
2009: Chevallier P; Labopin M; Nagler A; Ljungman P; Verdonck L F; Volin L; Zander A R; Finke J; Socie G; Cordonnier C; Harousseau J-L; Mohty M; Rocha V;
Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT.
Bone marrow transplantation 2009;44(9):589-94.
2009: Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Flandrois G; Devys A; Stocco V; Cesbron A; Dehaut F; Moreau P; Harousseau J-L; Mohty M
Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors.
Bone marrow transplantation 2009;44(9):613-5.
2009: Harousseau Jean-Luc
Hematopoietic stem cell transplantation in multiple myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(9):961-70.
2009: Harousseau Jean-Luc; Attal Michel; Avet-Loiseau Herve
The role of complete response in multiple myeloma.
Blood 2009;114(15):3139-46.
2009: Louw Vernon J; Louw Hymne; Webb Michael J
Autologous stem-cell transplantation for multiple myeloma.
The New England journal of medicine 2009;361(11):1118-9; author reply 1119.
2009: Avet-Loiseau Hervé; Li Cheng; Magrangeas Florence; Gouraud Wilfried; Charbonnel Catherine; Harousseau Jean-Luc; Attal Michel; Marit Gerald; Mathiot Claire; Facon Thierry; Moreau Philippe; Anderson Kenneth C; Campion Loïc; Munshi Nikhil C; Minvielle Stéphane
Prognostic significance of copy-number alterations in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4585-90.
2009: Cassinat Bruno; de Botton Stéphane; Kelaidi Charikleia; Ades Lionel; Zassadowski Fabien; Guillemot Isabelle; Schlageter Marie-Helene; Raffoux Emmanuel; Harousseau Jean-Luc; Legrand Olivier; Escoffre-Barbe Martine; Reman Oumedaly; Gardembas Martine; Himberlin Chantal; Cahn Jean Yves; Guyotat Denis; Bouscary Didier; Parry Anne; Rousselot Philippe; Baruchel Andre; Dombret Hervé; Chevret Sylvie; Fenaux Pierre; Chomienne Christine
When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).
Leukemia research 2009;33(9):1178-82.
2009: Kyriakou Charalampia; Canals Carmen; Finke Jürgen; Kobbe Guido; Harousseau Jean-Luc; Kolb Hans-Jochem; Novitzky Nicolas; Goldstone Anthony H; Sureda Anna; Schmitz Norbert
Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(24):3951-8.
2009: Harousseau Jean-Luc; Martinelli Giovanni; Jedrzejczak Wieslaw W; Brandwein Joseph M; Bordessoule Dominique; Masszi Tamas; Ossenkoppele Gert J; Alexeeva Julia A; Beutel Gernot; Maertens Johan; Vidriales Maria-Belen; Dombret Hervé; Thomas Xavier; Burnett Alan K; Robak Tadeusz; Khuageva Nuriet K; Golenkov Anatoly K; Tothova Elena; Mollgard Lars; Park Youn C; Bessems Annick; De Porre Peter; Howes Angela J;
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Blood 2009;114(6):1166-73.
2009: Chevallier Patrice; Hunault-Berger Mathilde; Larosa Fabrice; Dauriac Charles; Garand Richard; Harousseau Jean-Luc
A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial.
Leukemia research 2009;33(8):1124-6.
2009: Mohty Mohamad; Rocha Vanderson; Chevallier Patrice; Harousseau Jean-Luc; Nagler Arnon
Reduced-intensity conditioning for allogeneic stem cell transplantation: 10 years later.
Current opinion in oncology 2009;21 Suppl 1():S1.
2009: Harousseau Jean-Luc; Moreau Philippe
Autologous hematopoietic stem-cell transplantation for multiple myeloma.
The New England journal of medicine 2009;360(25):2645-54.
2009: Harousseau J-L; Dreyling M;
Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 4():97-9.
2009: Attal Michel; Harousseau Jean-Luc
The role of high-dose therapy with autologous stem cell support in the era of novel agents.
Seminars in hematology 2009;46(2):127-32.
2009: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Bladé Joan; Boccadoro Mario; Cavenagh Jamie D; Boral Anthony L; Esseltine Dixie-Lee; Wen Patrick Y; Amato Anthony A; Anderson Kenneth C; San Miguel Jesus
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
British journal of haematology 2009;144(6):895-903.
2009: Palumbo Antonio; Dimopoulos Meletios; San Miguel Jesus; Harousseau Jean-Luc; Attal Michel; Hussein Mohamad; Knop Stefan; Ludwig Heinz; von Lilienfeld-Toal Marie; Sonneveld Pieter
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Blood reviews 2009;23(2):87-93.
2009: Rodrigues Celso A; Sanz Guillermo; Brunstein Claudio G; Sanz Jaime; Wagner John E; Renaud Marc; de Lima Marcos; Cairo Mitchell S; Fürst Sabine; Rio Bernard; Dalley Christopher; Carreras Enric; Harousseau Jean-Luc; Mohty Mohamad; Taveira Denis; Dreger Peter; Sureda Anna; Gluckman Eliane; Rocha Vanderson
Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):256-63.
2009: Fagnoni Philippe; Milpied Noel; Limat Samuel; Deconinck Eric; Nerich Virginie; Foussard Charles; Colombat Philippe; Harousseau Jean-Luc; Woronoff-Lemsi Marie-Christine;
Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma.
PharmacoEconomics 2009;27(1):55-68.
2008: Bladé Joan; Sonneveld Pieter; San Miguel Jesús F; Sutherland Heather J; Hajek Roman; Nagler Arnon; Spencer Andrew; Robak Tadeusz; Cibeira M Teresa; Zhuang Sen H; Harousseau Jean-Luc; Orlowski Robert Z;
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Clinical lymphoma & myeloma 2008;8(6):352-5.
2008: Chevallier Patrice; Robillard Nelly; Ayari Sameh; Guillaume Thierry; Delaunay Jacques; Mechinaud Francoise; Avet-Loiseau Herve; Mohty Mohamad; Harousseau Jean-Luc; Garand Richard
Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
British journal of haematology 2008;143(5):744-6.
2008: Moreau Philippe; Coiteux Valerie; Hulin Cyrille; Leleu Xavier; van de Velde Helgi; Acharya Milin; Harousseau Jean-Luc
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
Haematologica 2008;93(12):1908-11.
2008: Moreau Philippe; Garban Frédéric; Attal Michel; Michallet Mauricette; Marit Gérald; Hulin Cyrille; Benboubker Lotfi; Doyen Chantal; Mohty Mohamad; Yakoub-Agha Ibrahim; Leyvraz Serge; Casassus Philippe; Avet-Loiseau Hervé; Garderet Laurent; Mathiot Claire; Harousseau Jean-Luc;
Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.
Blood 2008;112(9):3914-5.
2008: Chevallier Patrice; Delaunay Jacques; Turlure Pascal; Pigneux Arnaud; Hunault Mathilde; Garand Richard; Guillaume Thierry; Avet-Loiseau Herve; Dmytruk Nathalia; Girault Stephane; Milpied Noel; Ifrah Norbert; Mohty Mohamad; Harousseau Jean-Luc
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(32):5192-7.
2008: Lonial Sagar; Richardson Paul G; San Miguel Jesús; Sonneveld Pieter; Schuster Michael W; Bladé Joan; Cavenagh Jamie; Rajkumar S Vincent; Jakubowiak Andrzej J; Esseltine Dixie-Lee; Anderson Kenneth C; Harousseau Jean-Luc
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
British journal of haematology 2008;143(2):222-9.
2008: Chanan-Khan Asher; Sonneveld Pieter; Schuster Michael W; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Neuwirth Rachel; Anderson Kenneth C; Richardson Paul G
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4784-90.
2008: Chevallier Patrice; Mohty Mohamad; Lioure Bruno; Michel Gerard; Contentin Nathalie; Deconinck Eric; Bordigoni Pierre; Vernant Jean-Paul; Hunault Mathilde; Vigouroux Stéphane; Blaise Didier; Tabrizi Reza; Buzyn Agnes; Socie Gerard; Michallet Mauricette; Volteau Christelle; Harousseau Jean-Luc
Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4940-3.
2008: Decaux Olivier; Lodé Laurence; Magrangeas Florence; Charbonnel Catherine; Gouraud Wilfried; Jézéquel Pascal; Attal Michel; Harousseau Jean-Luc; Moreau Philippe; Bataille Régis; Campion Loïc; Avet-Loiseau Hervé; Minvielle Stéphane;
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4798-805.
2008: Niesvizky Ruben; Richardson Paul G; Rajkumar S Vincent; Coleman Morton; Rosiñol Laura; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Boral Anthony L; Esseltine Dixie-Lee; Anderson Kenneth C; Bladé Joan
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
British journal of haematology 2008;143(1):46-53.
2008: Chevallier Patrice; Mahe Beatrice; Garand Richard; Talmant Pascaline; Harousseau Jean-Luc; Delaunay Jacques
Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
International journal of hematology 2008;88(2):209-11.
2008: Tichelli André; Passweg Jakob; Wójcik Dorota; Rovó Alicia; Harousseau Jean-Luc; Masszi Tamas; Zander Axel; Békássy Albert; Crawley Charles; Arat Mutlu; Sica Simona; Lutz Patrick; Socié Gérard;
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.
Haematologica 2008;93(8):1203-10.
2008: Chevallier Patrice; Touzeau Cyril; Ayari Sameh; Guillaume Thierry; Harousseau Jean-Luc; Delaunay Jacques
Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity.
Leukemia research 2008;32(8):1321-2.
2008: Harousseau J-L
New treatments in multiple myeloma: beyond optimal treatment.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 5():v68-70.
2008: Gorin Norbert-Claude; Labopin Myriam; Frassoni Francesco; Milpied Noel; Attal Michel; Blaise Didier; Meloni Giovanna; Iori Anna P; Michallet Mauricette; Willemze Roel; Deconninck Eric; Harousseau Jean-Luc; Polge Emmanuelle; Rocha Vanderson
Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(19):3183-8.
2008: Harousseau J L
Maintenance treatment in multiple myeloma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 4():iv54-5.
2008: San-Miguel Jesús; Harousseau Jean-Luc; Joshua Douglas; Anderson Kenneth C
Individualizing treatment of patients with myeloma in the era of novel agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2761-6.
2008: Chevallier Patrice; Al Nawakil Chadi; Vigouroux Stephane; Talmant Pascaline; Harousseau Jean-Luc; Garand Richard
Two cases of acute lymphoblastic leukaemia following acute myeloid leukaemia.
Leukemia research 2008;32(6):1001-3.
2008: Harousseau J-L; Dreyling M;
Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 2():ii55-7.
2008: Sonneveld Pieter; Hajek Roman; Nagler Arnon; Spencer Andrew; Bladé Joan; Robak Tadeusz; Zhuang Sen H; Harousseau Jean-Luc; Orlowski Robert Z;
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Cancer 2008;112(7):1529-37.
2008: Ludwig Heinz; Durie Brian G M; Bolejack Vanessa; Turesson Ingemar; Kyle Robert A; Blade Joan; Fonseca Rafael; Dimopoulos Meletios; Shimizu Kazuyuki; San Miguel Jesus; Westin Jan; Harousseau Jean-Luc; Beksac Meral; Boccadoro Mario; Palumbo Antonio; Barlogie Bart; Shustik Chaim; Cavo Michele; Greipp Philip R; Joshua Douglas; Attal Michel; Sonneveld Pieter; Crowley John
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.
Blood 2008;111(8):4039-47.
2008: Palumbo Antonio; Facon Thierry; Sonneveld Pieter; Bladè Joan; Offidani Massimo; Gay Francesca; Moreau Philippe; Waage Anders; Spencer Andrew; Ludwig Heinz; Boccadoro Mario; Harousseau Jean-Luc
Thalidomide for treatment of multiple myeloma: 10 years later.
Blood 2008;111(8):3968-77.
2008: Terrier Benjamin; Jaccard Arnaud; Harousseau Jean-Luc; Delarue Richard; Tournilhac Olivier; Hunault-Berger Mathilde; Hamidou Mohamed; Dantal Jacques; Bernard Marc; Grosbois Bernard; Morel Pierre; Coiteux Valérie; Gisserot Olivier; Rodon Philippe; Hot Arnaud; Elie Caroline; Leblond Véronique; Fermand Jean-Paul; Fakhouri Fadi
The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.
Medicine 2008;87(2):99-109.
2008: Bodet-Milin Caroline; Kraeber-Bodéré Françoise; Dupas Benoît; Morschhauser Franck; Gastinne Thomas; Le Gouill Steven; Campion Loïc; Harousseau Jean-Luc; Wegener William A; Goldenberg David M; Huglo Damien
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Haematologica 2008;93(3):390-7.
2008: Royer Pierre-Joseph; Bougras Gwenola; Ebstein Frederic; Leveque Lucie; Tanguy-Royer Severine; Simon Thomas; Juge-Morineau Nadine; Chevallier Patrice; Harousseau Jean-Luc; Gregoire Marc
Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
Experimental hematology 2008;36(3):329-39.
2008: Raponi Mitch; Lancet Jeffrey E; Fan Hongtao; Dossey Lesley; Lee Grace; Gojo Ivana; Feldman Eric J; Gotlib Jason; Morris Lawrence E; Greenberg Peter L; Wright John J; Harousseau Jean-Luc; Löwenberg Bob; Stone Richard M; De Porre Peter; Wang Yixin; Karp Judith E
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Blood 2008;111(5):2589-96.
2008: Bataille Régis; Pellat-Deceunynck Catherine; Robillard Nelly; Avet-Loiseau Hervé; Harousseau Jean-Luc; Moreau Philippe
CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis.
Leukemia research 2008;32(3):379-82.
2007: Attal Michel; Harousseau Jean-Luc
Role of autologous stem-cell transplantation in multiple myeloma.
Best practice & research. Clinical haematology 2007;20(4):747-59.
2007: Harousseau Jean-Luc
New insights into the biology and advances in the management of multiple myeloma.
Best practice & research. Clinical haematology 2007;20(4):569-70.
2007: Hunault Mathilde; Truchan-Graczyk Malgorzata; Caillot Denis; Harousseau Jean-Luc; Bologna Serge; Himberlin Chantal; Guyotat Denis; Berthou Christian; Casassus Philippe; Baranger Laurence; Béné Marie-Christine; Ifrah Norbert; Gyan Emmanuel;
Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial.
Haematologica 2007;92(12):1623-30.
2007: Harousseau Jean-Luc
Role of stem cell transplantation.
Hematology/oncology clinics of North America 2007;21(6):1157-74, x.
2007: Dimopoulos Meletios; Spencer Andrew; Attal Michael; Prince H Miles; Harousseau Jean-Luc; Dmoszynska Anna; San Miguel Jesus; Hellmann Andrzej; Facon Thierry; Foà Robin; Corso Alessandro; Masliak Zvenyslava; Olesnyckyj Marta; Yu Zhinuan; Patin John; Zeldis Jerome B; Knight Robert D;
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
The New England journal of medicine 2007;357(21):2123-32.
2007: Richardson Paul G; Sonneveld Pieter; Schuster Michael; Irwin David; Stadtmauer Edward; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Miguel Jesus San; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Alsina Melissa; Rajkumar S Vincent; Lacy Martha; Jakubowiak Andrzej; Dalton William; Boral Anthony; Esseltine Dixie-Lee; Schenkein David; Anderson Kenneth C
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Blood 2007;110(10):3557-60.
2007: Le Gouill Steven; Talmant Pascaline; Touzeau Cyrille; Moreau Anne; Garand Richard; Juge-Morineau Nadine; Gaillard Fanny; Gastinne Thomas; Milpied Noël; Moreau Philippe; Harousseau Jean Luc; Avet-Loiseau Hervé
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
Haematologica 2007;92(10):1335-42.
2007: Facon Thierry; Mary Jean Yves; Hulin Cyrille; Benboubker Lotfi; Attal Michel; Pegourie Brigitte; Renaud Marc; Harousseau Jean Luc; Guillerm Gaëlle; Chaleteix Carine; Dib Mamoun; Voillat Laurent; Maisonneuve Hervé; Troncy Jacques; Dorvaux Véronique; Monconduit Mathieu; Martin Claude; Casassus Philippe; Jaubert Jérôme; Jardel Henry; Doyen Chantal; Kolb Brigitte; Anglaret Bruno; Grosbois Bernard; Yakoub-Agha Ibrahim; Mathiot Claire; Avet-Loiseau Hervé;
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Lancet 2007;370(9594):1209-18.
2007: Gastinne Thomas; Leleu Xavier; Duhamel Alain; Moreau Anne-Sophie; Franck Genevieve; Andrieux Joris; Lai Jean-Luc; Coiteux Valerie; Yakoub-Agha Ibrahim; Bauters Francis; Harousseau Jean-Luc; Zandecki Marc; Facon Thierry;
Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
European journal of haematology 2007;79(4):297-304.
2007: Orlowski Robert Z; Nagler Arnon; Sonneveld Pieter; Bladé Joan; Hajek Roman; Spencer Andrew; San Miguel Jesús; Robak Tadeusz; Dmoszynska Anna; Horvath Noemi; Spicka Ivan; Sutherland Heather J; Suvorov Alexander N; Zhuang Sen H; Parekh Trilok; Xiu Liang; Yuan Zhilong; Rackoff Wayne; Harousseau Jean-Luc
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3892-901.
2007: Moreau P; Attal M; Garban F; Hulin C; Facon T; Marit G; Michallet M; Doyen C; Leyvraz S; Mohty M; Wetterwald M; Mathiot C; Caillot D; Berthou C; Benboubker L; Garderet L; Chaleteix C; Traullé C; Fuzibet J G; Jaubert J; Lamy T; Casassus P; Dib M; Kolb B; Dorvaux V; Grosbois B; Yakoub-Agha I; Harousseau J L; Avet-Loiseau H;
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(9):2020-4.
2007: Harousseau Jean-Luc
Farnesyltransferase inihibitors in hematologic malignancies.
Blood reviews 2007;21(4):173-82.
2007: Moreau Philippe; Harousseau Jean-Luc; Attal Michel
Allografting or autografting for myeloma.
The New England journal of medicine 2007;356(25):2646-8; author reply 2646-8.
2007: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; San Miguel Jesús-F; Cavenagh Jamie D; Anderson Kenneth C
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
British journal of haematology 2007;137(5):429-35.
2007: Harousseau Jean-Luc; Lancet Jeffrey E; Reiffers Josy; Lowenberg Bob; Thomas Xavier; Huguet Francoise; Fenaux Pierre; Zhang Steven; Rackoff Wayne; De Porre Peter; Stone Richard;
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
Blood 2007;109(12):5151-6.
2007: Raponi Mitch; Harousseau Jean-Luc; Lancet Jeffrey E; Löwenberg Bob; Stone Richard; Zhang Yi; Rackoff Wayne; Wang Yixin; Atkins David
Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2254-60.
2007: Moreau P; Voillat L; Benboukher L; Mathiot C; Dumontet C; Robillard N; Hérault O; Garnache F; Garand R; Varoqueaux N; Avet-Loiseau H; Harousseau J L; Bataille R;
Rituximab in CD20 positive multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(4):835-6.
2007: Armand Jean-Pierre; Burnett Alan K; Drach Johannes; Harousseau Jean-Luc; Löwenberg Bob; San Miguel Jesús
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
The oncologist 2007;12(3):281-90.
2007: Harousseau Jean-Luc; Moreau Philippe
Role of bone marrow transplantation in the disease pathway of myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):163-9.
2007: Touzeau C; Pellat-Deceunynck C; Gastinne T; Accard F; Jego G; Avet-Loiseau H; Robillard N; Harousseau J L; Bataille R; Moreau P
Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications.
Leukemia & lymphoma 2007;48(1):207-8.
2007: Jagannath S; Richardson P G; Sonneveld P; Schuster M W; Irwin D; Stadtmauer E A; Facon T; Harousseau J-L; Cowan J M; Anderson K C
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(1):151-7.
2007: Attal Michel; Moreau Philippe; Avet-Loiseau Herve; Harousseau Jean-Luc
Stem cell transplantation in multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2007;():311-6.
2006: Harousseau Jean-Luc; Attal Michel; Leleu Xavier; Troncy Jacques; Pegourie Brigitte; Stoppa Anne-Marie; Hulin Cyrille; Benboubker Lofti; Fuzibet Jean-Gabriel; Renaud Marc; Moreau Philippe; Avet-Loiseau Hervé
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Haematologica 2006;91(11):1498-505.
2006: Attal Michel; Harousseau Jean-Luc; Leyvraz Serge; Doyen Chantal; Hulin Cyrille; Benboubker Lofti; Yakoub Agha Ibrahim; Bourhis Jean-Henri; Garderet Laurent; Pegourie Brigitte; Dumontet Charles; Renaud Marc; Voillat Laurent; Berthou Christian; Marit Gerald; Monconduit Mathieu; Caillot Denis; Grobois Bernard; Avet-Loiseau Herve; Moreau Philippe; Facon Thierry;
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Blood 2006;108(10):3289-94.
2006: Querellou Solène; Valette Frédéric; Bodet-Milin Caroline; Oudoux Aurore; Carlier Thomas; Harousseau Jean-Luc; Chatal Jean-François; Couturier Olivier
FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Annals of hematology 2006;85(11):759-67.
2006: Harousseau Jean-Luc
Thalidomide in multiple myeloma: past, present and future.
Future oncology (London, England) 2006;2(5):577-89.
2006: Barlogie Bart; Tricot Guido J; van Rhee Frits; Angtuaco Edguardo; Walker Ron; Epstein Joshua; Shaughnessy John D; Jagannath Sundar; Bolejack Vanessa; Gurley Jennifer; Hoering Antje; Vesole David; Desikan Raman; Siegel David; Mehta Jayesh; Singhal Seema; Munshi Nikhil C; Dhodapkar Madhav; Jenkins Bonnie; Attal Michel; Harousseau Jean-Luc; Crowley John
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
British journal of haematology 2006;135(2):158-64.
2006: Harousseau Jean-Luc
[A cure for multiple myeloma?]
Presse médicale (Paris, France : 1983) 2006;35(9 Pt 2):1288-90.
2006: Bataille Régis; Jégo Gaëtan; Robillard Nelly; Barillé-Nion Sophie; Harousseau Jean-Luc; Moreau Philippe; Amiot Martine; Pellat-Deceunynck Catherine
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.
Haematologica 2006;91(9):1234-40.
2006: Menoret Emmanuelle; Gomez-Bougie Patricia; Geffroy-Luseau Alexandrine; Daniels Sylvanne; Moreau Philippe; Le Gouill Steven; Harousseau Jean-Luc; Bataille Regis; Amiot Martine; Pellat-Deceunynck Catherine
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells.
Blood 2006;108(4):1346-52.
2006: Harousseau Jean-Luc
[Jean Bernard.]
Bulletin du cancer 2006;93(7):659.
2006: Vigouroux Stéphane; Morin Odile; Moreau Philippe; Harousseau Jean-Luc; Milpied Noel
Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center.
Haematologica 2006;91(5):717-8.
2006: Garban Frederic; Attal Michel; Michallet Mauricette; Hulin Cyrille; Bourhis Jean H; Yakoub-Agha Ibrahim; Lamy Thierry; Marit Gerald; Maloisel Frederic; Berthou Christian; Dib Mamoun; Caillot Denis; Deprijck Bernard; Ketterer Nicolas; Harousseau Jean-Luc; Sotto Jean-Jacques; Moreau Philippe
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
Blood 2006;107(9):3474-80.
2006: Moreau Philippe; Robillard Nelly; Jégo Gaétan; Pellat Catherine; Le Gouill Steven; Thoumi Soraya; Avet-Loiseau Hervé; Harousseau Jean-Luc; Bataille Régis
Lack of CD27 in myeloma delineates different presentation and outcome.
British journal of haematology 2006;132(2):168-70.
2006: Moreau Philippe; Hullin Cyrille; Garban Frédéric; Yakoub-Agha Ibrahim; Benboubker Lotfi; Attal Michel; Marit Gérald; Fuzibet Jean-Gabriel; Doyen Chantal; Voillat Laurent; Berthou Christian; Ketterer Nicolas; Casassus Philippe; Monconduit Mathieu; Michallet Mauricette; Najman Albert; Sotto Jean-Jacques; Bataille Régis; Harousseau Jean-Luc;
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.
Blood 2006;107(1):397-403.
2006: Dicato Mario; Boccadoro Mario; Cavenagh Jamie; Harousseau Jean-Luc; Ludwig Heinz; San Miguel Jesús; Sonneveld Pieter
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Oncology 2006;70(6):474-82.
2005: Vigouroux Stéphane; Gaillard Fanny; Moreau Philippe; Harousseau Jean-Luc; Milpied Noël
High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma.
Haematologica 2005;90(11):1580-2.
2005: Harousseau Jean-Luc; Moreau Philippe
Evolving role of stem cell transplantation in multiple myeloma.
Clinical lymphoma & myeloma 2005;6(2):89-95.
2005: Chevallier Patrice; Roland Virginie; Mahé Béatrice; Juge-Morineau Nadine; Dubruille Viviane; Guillaume Thierry; Vigouroux Stéphane; Moreau Philippe; Milpied Noël; Garand Richard; Avet-Loiseau Herve; Harousseau Jean-Luc
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Leukemia research 2005;29(9):1003-7.
2005: Sujobert Pierre; Bardet Valerie; Cornillet-Lefebvre Pascale; Hayflick Joel S; Prie Nolwen; Verdier Frederic; Vanhaesebroeck Bart; Muller Odile; Pesce Florence; Ifrah Norbert; Hunault-Berger Mathilde; Berthou Christian; Villemagne Bruno; Jourdan Eric; Audhuy Bruno; Solary Eric; Witz Brigitte; Harousseau Jean Luc; Himberlin Chantal; Lamy Thierry; Lioure Bruno; Cahn Jean Yves; Dreyfus Francois; Mayeux Patrick; Lacombe Catherine; Bouscary Didier
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.
Blood 2005;106(3):1063-6.
2005: Wuillème-Toumi S; Robillard N; Gomez P; Moreau P; Le Gouill S; Avet-Loiseau H; Harousseau J-L; Amiot M; Bataille R
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(7):1248-52.
2005: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; San-Miguel Jesus F; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Dalton William S; Boral Anthony L; Esseltine Dixie L; Porter Jane B; Schenkein David; Anderson Kenneth C;
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
The New England journal of medicine 2005;352(24):2487-98.
2005: Denis Laure; Gagne Katia; Gueglio Brigitte; Kerdudou Nolwenn; Milpied Noel; Simon Philippe; Follea Gilles; Bonneville Marc; Harousseau Jean-Luc; Bignon Jean-Denis
NK-KIR transcript kinetics correlate with acute graft-versus-host disease occurrence after allogeneic bone marrow transplantation.
Human immunology 2005;66(5):447-59.
2005: Bataille Régis; Robillard Nelly; Avet-Loiseau Hervé; Harousseau Jean-Luc; Moreau Philippe
CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.
Haematologica 2005;90(5):706-7.
2005: Harousseau Jean-Luc
Stem cell transplantation in multiple myeloma (0, 1, or 2).
Current opinion in oncology 2005;17(2):93-8.
2005: Vigouroux Stéphane; Morin Odile; Moreau Philippe; Méchinaud Françoise; Morineau Nadine; Mahé Béatrice; Chevallier Patrice; Guillaume Thierry; Dubruille Viviane; Harousseau Jean-Luc; Milpied Noël
Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(4):e35-7.
2005: Wuilleme S; Robillard N; Lodé L; Magrangeas F; Beris H; Harousseau J-L; Proffitt J; Minvielle S; Avet-Loiseau H;
Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(2):275-8.
2005: Harousseau Jean-Luc; Moreau Philippe; Attal Michel; Facon Thierry; Avet-Loiseau Hervé
Stem-cell transplantation in multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):603-18.
2004: Harousseau Jean-Luc
New strategies in transplantation therapy.
Oncology (Williston Park, N.Y.) 2004;18(13):1614-5, 1617.
2004: Chevallier Patrice; Robillard Nelly; Wuilleme-Toumi Soraya; Méchinaud Françoise; Harousseau Jean-Luc; Avet-Loiseau Hervé
Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients.
Haematologica 2004;89(11):1399-401.
2004: Hunault Mathilde; Harousseau Jean-Luc; Delain Martine; Truchan-Graczyk Malgorzata; Cahn Jean-Yves; Witz Francis; Lamy Thierry; Pignon Bernard; Jouet Jean-Pierre; Garidi Reda; Caillot Denis; Berthou Christian; Guyotat Denis; Sadoun Alain; Sotto Jean-Jacques; Lioure Bruno; Casassus Philippe; Solal-Celigny Philippe; Stalnikiewicz Laure; Audhuy Bruno; Blanchet Odile; Baranger Laurence; Béné Marie-Christine; Ifrah Norbert;
Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial.
Blood 2004;104(10):3028-37.
2004: Le Gouill Steven; Podar Klaus; Amiot Martine; Hideshima Teru; Chauhan Dharminder; Ishitsuka Kenji; Kumar Shaji; Raje Noopur; Richardson Paul G; Harousseau Jean-Luc; Anderson Kenneth C
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.
Blood 2004;104(9):2886-92.
2004: Le Gouill Steven; Podar Klaus; Harousseau Jean-Luc; Anderson Kenneth C
Mcl-1 regulation and its role in multiple myeloma.
Cell cycle (Georgetown, Tex.) 2004;3(10):1259-62.
2004: Blin Nicolas; Morineau Nadine; Gaillard Fanny; Morin Odile; Milpied Noël; Harousseau Jean-Luc; Moreau Philippe
Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 2004;45(10):2161-3.
2004: Khayat David; Rixe Olivier; Brunet René; Goupil Alain; Bugat Roland; Harousseau Jean-Luc; Ifrah Norbert; Puozzo Christian
Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
Cancer chemotherapy and pharmacology 2004;54(3):193-205.
2004: Moreau Philippe; Robillard Nelly; Avet-Loiseau Herve; Pineau Danielle; Morineau Nadine; Milpied Noel; Harousseau Jean-Luc; Bataille Regis
Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.
Haematologica 2004;89(5):547-51.
2004: Magrangeas Florence; Cormier Marie-Laure; Descamps Géraldine; Gouy Nadège; Lodé Laurence; Mellerin Marie-Paule; Harousseau Jean-Luc; Bataille Régis; Minvielle Stéphane; Avet-Loiseau Hervé
Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level.
Blood 2004;103(10):3869-75.
2004: Milpied Noel; Deconinck Eric; Gaillard Fanny; Delwail Vincent; Foussard Charles; Berthou Christian; Gressin Remy; Lucas Virginie; Colombat Philippe; Harousseau Jean-Luc;
Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.
The New England journal of medicine 2004;350(13):1287-95.
2004: Harousseau Jean-Luc; Shaughnessy John; Richardson Paul
Multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2004;():237-56.
2004: Witz F; Harousseau J L; Guilhot F; Cahn J Y; Witz B; Loos C; Chevalier M P; Guibon O; Berthaud P; Lioure B;
Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM data.
Annals of hematology 2004;83 Suppl 1():S55-7.
2003: Attal Michel; Harousseau Jean-Luc; Facon Thierry; Guilhot François; Doyen Chantal; Fuzibet Jean-Gabriel; Monconduit Mathieu; Hulin Cyrille; Caillot Denis; Bouabdallah Reda; Voillat Laurent; Sotto Jean-Jacques; Grosbois Bernard; Bataille Regis;
Single versus double autologous stem-cell transplantation for multiple myeloma.
The New England journal of medicine 2003;349(26):2495-502.
2003: Garand R; Avet-Loiseau H; Accard F; Moreau P; Harousseau J L; Bataille R
t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(10):2032-5.
2003: Borchmann Peter; Morschhauser Franck; Parry Anne; Schnell Roland; Harousseau Jean Luc; Gisselbrecht Christian; Rudolph Christian; Wilhelm Martin; Günther Hans; Pfreundschuh Derigs Michael; Camboni Gabriella; Engert Andreas
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
Haematologica 2003;88(8):888-94.
2003: Wajcman Henri; Bardakdjian-Michau Josiane; Riou Jean; Préhu Claude; Kister Jean; Baudin-Creuza Véronique; Promé Danielle; Richelme-David Suzy; Harousseau Jean Luc; Galactéros Fréderic
Two new hemoglobin variants with increased oxygen affinity: Hb Nantes [beta34(B16)Val-->Leu] and Hb Vexin [beta116(G18)His-->Leu].
Hemoglobin 2003;27(3):191-9.
2003: Robillard Nelly; Avet-Loiseau Herve; Garand Richard; Moreau Philippe; Pineau Danielle; Rapp Marie-Josee; Harousseau Jean-Luc; Bataille Regis
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.
Blood 2003;102(3):1070-1.
2003: Solary Eric; Drenou Bernard; Campos Lydia; de Crémoux Patricia; Mugneret Francine; Moreau Philippe; Lioure Bruno; Falkenrodt Annie; Witz Brigitte; Bernard Marc; Hunault-Berger Mathilde; Delain Martine; Fernandes José; Mounier Christiane; Guilhot François; Garnache Francine; Berthou Christian; Kara-Slimane Fawzi; Harousseau Jean-Luc;
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia.
Blood 2003;102(4):1202-10.
2003: Harousseau Jean-Luc
[Autograft of hematopoietic stem cells in multiple myeloma]
Presse médicale (Paris, France : 1983) 2003;32(24):1107.
2003: Delaunay Jacques; Vey Norbert; Leblanc Thierry; Fenaux Pierre; Rigal-Huguet Françoise; Witz Francis; Lamy Thierry; Auvrignon Anne; Blaise Didier; Pigneux Arnaud; Mugneret Francine; Bastard Christian; Dastugue Nicole; Van den Akker Jacqueline; Fière Denis; Reiffers Josy; Castaigne Sylvie; Leverger Guy; Harousseau Jean-Luc; Dombret Herve;
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Blood 2003;102(2):462-9.
2003: Magrangeas Florence; Nasser Valéry; Avet-Loiseau Hervé; Loriod Béatrice; Decaux Olivier; Granjeaud Samuel; Bertucci François; Birnbaum Daniel; Nguyen Catherine; Harousseau Jean-Luc; Bataille Régis; Houlgatte Rémi; Minvielle Stéphane
Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.
Blood 2003;101(12):4998-5006.
2003: Harousseau Jean-Luc
Autologous stem cell transplantation in multiple myeloma: none, one, or two?
Current hematology reports 2003;2(3):171-2.
2003: Mahé B; Milpied N; Mellerin M P; Moreau P; Morineau N; Vigier M; Harousseau J L
PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.
Bone marrow transplantation 2003;31(6):467-73.
2003: Body Jean-Jacques; Greipp Philip; Coleman Robert E; Facon Thierry; Geurs Filip; Fermand Jean-Paul; Harousseau Jean-Luc; Lipton Allan; Mariette Xavier; Williams Catherine D; Nakanishi Arline; Holloway Donna; Martin Steven W; Dunstan Colin R; Bekker Pirow J
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Cancer 2003;97(3 Suppl):887-92.
2003: Avet-Loiseau Hervé; Garand Richard; Lodé Laurence; Harousseau Jean-Luc; Bataille Régis;
Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants.
Blood 2003;101(4):1570-1.
2003: Maloisel F; Benboubker L; Gardembas M; Coiffier B; Divine M; Sebban C; Blanc M; Abgrall J-F; Lederlin P; Harousseau J-L; Blaise A-M; Grosbois B; Morice P; Ghandour C; Castaigne S
Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(1):45-51.
2003: Durie Brian G M; Kyle Robert A; Belch Andrew; Bensinger William; Blade Joan; Boccadoro Mario; Child J Anthony; Comenzo Raymond; Djulbegovic Ben; Fantl Dorotea; Gahrton Gosta; Harousseau Jean Luc; Hungria Vania; Joshua Douglas; Ludwig Heinz; Mehta Jayesh; Morales Angelina Rodrique; Morgan Gareth; Nouel Amara; Oken Martin; Powles Raymond; Roodman David; San Miguel Jesus; Shimizu Kazuyuki; Singhal Seema; Sirohi Bhawna; Sonneveld Pieter; Tricot Guido; Van Ness Brian;
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(6):379-98.
2003: Harousseau Jean-Luc
[Intensive treatment of multiple myeloma]
Bulletin de l'Académie nationale de médecine 2003;187(2):405-13; discussion 413-5.
2003: Harousseau Jean-Luc; Attal Michel
High-dose therapy in multiple myeloma.
The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(3):163-70.
2002: Linassier Claude; Desablens Bernard; Lefrancq Thierry; Le Prise Pierre-Yves; Harousseau Jean-Luc; Jacob Claude; Gandhour Christine; Haillot Olivier; Lucas Virginie; Leloup Rémy; Escoffre Martine; Colombat Philippe; Tabuteau Stéphanie;
Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group.
Clinical lymphoma 2002;3(3):167-72.
2002: Harousseau Jean-Luc; Attal Michel
The role of stem cell transplantation in multiple myeloma.
Blood reviews 2002;16(4):245-53.
2002: Harousseau Jean-Luc
Management of multiple myeloma.
Reviews in clinical and experimental hematology 2002;6(3):253-75.
2002: Moreau P; Misbahi R; Milpied N; Morineau N; Mahé B; Vigier M; Rapp M J; Bataille R; Harousseau J L
Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(9):1838-43.
2002: Le Gouill S; Pellat-Deceunynck C; Harousseau J-L; Rapp M-J; Robillard N; Bataille R; Amiot M
Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(9):1664-7.
2002: Moreau Philippe; Facon Thierry; Leleu Xavier; Morineau Nadine; Huyghe Pauline; Harousseau Jean-Luc; Bataille Régis; Avet-Loiseau Hervé;
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.
Blood 2002;100(5):1579-83.
2002: Oliver Lisa; Vavasseur Fabienne; Mahé Beatrice; Perrin Pascale; Harousseau Jean-Luc; Meflah Khaled; Vallette François-Marie
Assessment of caspase activity as a possible prognostic factor in acute myeloid leukaemia.
British journal of haematology 2002;118(2):434-7.
2002: Derenne Sophie; Monia Brett; Dean Nicholas M; Taylor Jennifer K; Rapp Marie-Josée; Harousseau Jean-Luc; Bataille Régis; Amiot Martine
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
Blood 2002;100(1):194-9.
2002: Vigouroux S; Milpied N; Andrieu J M; Colonna P; Ifrah N; Colombat P; Desablens B; Abgrall J F; Casassus P; Guilhot F; Briere J; Le Mevel A; Moreau P; Mechinaud F; Mahe B; Morineau N; Vigier M; Rapp M J; Harousseau J L
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy.
Bone marrow transplantation 2002;29(10):833-42.
2002: Spisek Radek; Chevallier Patrice; Morineau Nadine; Milpied Noël; Avet-Loiseau Herve; Harousseau Jean-Luc; Meflah Khaled; Gregoire Marc
Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
Cancer research 2002;62(10):2861-8.
2002: Nguyen Stéphanie; Leblanc Thierry; Fenaux Pierre; Witz Francis; Blaise Didier; Pigneux Arnaud; Thomas Xavier; Rigal-Huguet Françoise; Lioure Bruno; Auvrignon Anne; Fière Denis; Reiffers Josy; Castaigne Sylvie; Leverger Guy; Harousseau Jean-Luc; Socié Gérard; Dombret Hervé
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.
Blood 2002;99(10):3517-23.
2002: Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Brière J; Abgrall J F; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque J P; Delain M; Harousseau J L; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F;
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(4):573-80.
2002: Avet-Loiseau Hervé; Facon Thierry; Grosbois Bernard; Magrangeas Florence; Rapp Marie-José; Harousseau Jean-Luc; Minvielle Stéphane; Bataille Régis;
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.
Blood 2002;99(6):2185-91.
2002: Le Gouill Steven; Moreau Philippe; Morineau Nadine; Harousseau Jean-Luc; Milpied Noël
Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study.
Haematologica 2002;87(3):333-4.
2002: Moreau Philippe; Facon Thierry; Attal Michel; Hulin Cyrille; Michallet Mauricette; Maloisel Frédéric; Sotto Jean-Jacques; Guilhot François; Marit Gérald; Doyen Chantal; Jaubert Jérôme; Fuzibet Jean-Gabriel; François Sylvie; Benboubker Lotfi; Monconduit Matthieu; Voillat Laurent; Macro Margaret; Berthou Christian; Dorvaux Véronique; Pignon Bernard; Rio Bernard; Matthes Thomas; Casassus Philippe; Caillot Denis; Najman Norbert; Grosbois Bernard; Bataille Régis; Harousseau Jean-Luc;
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
Blood 2002;99(3):731-5.
2002: Chevallier Patrice; Penther Dominique; Avet-Loiseau Hervé; Robillard Nelly; Ifrah Norbert; Mahé Béatrice; Hamidou Mohamed; Maisonneuve Hervé; Moreau Philippe; Jardel Henri; Harousseau Jean Luc; Bataille Régis; Garand Richard
CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia.
British journal of haematology 2002;116(1):142-50.
2002: Anderson Kenneth C; Shaughnessy John D; Barlogie Bart; Harousseau Jean-Luc; Roodman G David
Multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():214-40.
2002: Harousseau J-L
High-dose therapy in multiple myeloma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13 Suppl 4():49-54.
2002: Yakoub-Agha Ibrahim; Attal Michel; Dumontet Charles; Delannoy Válerie; Moreau Philippe; Berthou Christian; Lamy Thierney; Grosbois Bernard; Dauriac Charly; Dorvaux Véronique; Bay Jacques-Olivier; Monconduit Matthieu; Harousseau Jean Luc; Duguet Corinne; Duhamel Alain; Facon Thierry
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
The hematology journal : the official journal of the European Haematology Association / EHA 2002;3(4):185-92.
2001: Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau J L; Bataille R;
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
Blood 2001;98(10):3082-6.
2001: Leblond V; Lévy V; Maloisel F; Cazin B; Fermand J P; Harousseau J L; Remenieras L; Porcher R; Gardembas M; Marit G; Deconinck E; Desablens B; Guilhot F; Philippe G; Stamatoullas A; Guibon O;
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.
Blood 2001;98(9):2640-4.
2001: Bezieau S; Devilder M C; Avet-Loiseau H; Mellerin M P; Puthier D; Pennarun E; Rapp M J; Harousseau J L; Moisan J P; Bataille R
High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.
Human mutation 2001;18(3):212-24.
2001: Lévy V; Porcher R; Leblond V; Fermand J P; Cazin B; Maloisel F; Harousseau J L; Remenieras L; Guibon O; Chevret S;
Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(9):1466-70.
2001: Ninin E; Milpied N; Moreau P; André-Richet B; Morineau N; Mahé B; Vigier M; Imbert B M; Morin O; Harousseau J L; Richet H
Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(1):41-7.
2001: Facon T; Avet-Loiseau H; Guillerm G; Moreau P; Geneviève F; Zandecki M; Laï J L; Leleu X; Jouet J P; Bauters F; Harousseau J L; Bataille R; Mary J Y;
Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
Blood 2001;97(6):1566-71.
2001: Puthier D; Thabard W; Rapp M; Etrillard M; Harousseau J; Bataille R; Amiot M
Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule.
British journal of haematology 2001;112(2):358-63.
2001: Thomas O; Mahé M; Campion L; Bourdin S; Milpied N; Brunet G; Lisbona A; Le Mevel A; Moreau P; Harousseau J; Cuillière J
Long-term complications of total body irradiation in adults.
International journal of radiation oncology, biology, physics 2001;49(1):125-31.
2000: Brice P; Simon D; Bouabdallah R; Bélanger C; Haïoun C; Thieblemont C; Tilly H; Harousseau J L; Doyen C; Martin C; Brousse N; Solal-Céligny P H;
High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(12):1585-90.
2000: Vigouroux S; Morin O; Milpied N; Mahé B; Rapp M J; Harousseau J L
[Cryptococcus neoformans infection in hematologic malignancies]
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 2000;21(11):955-60.
2000: Morineau N; Tang X W; Moreau P; Milpied N; Mahé B; Bataille R; Harousseau J L
Lack of benefit of CD34+ cell selected over non-selected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(10):1815-20.
2000: Jego G; Avet-Loiseau H; Robillard N; Moreau P; Amiot M; Harousseau J; Pellat-Deceunynck C; Bataille R
Reactive plasmacytoses in multiple myeloma during hematopoietic recovery with G- or GM-CSF.
Leukemia research 2000;24(7):627-30.
2000: Mahé M a; Bourdin S; Le Pourhiet-Le Mevel A; Moreau P; Campion L; Hamidou M; Milpied N; Moreau A; Gaillard F; Harousseau J L; Cuillière J C
Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy.
International journal of radiation oncology, biology, physics 2000;47(3):735-8.
2000: Le Gouill S; Talmant P; Milpied N; Daviet A; Ancelot M; Moreau P; Harousseau J L; Bataille R; Avet-Loiseau H
Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(7):1533-8.
2000: Pellat-Deceunynck C; Mellerin M P; Labarrière N; Jego G; Moreau-Aubry A; Harousseau J L; Jotereau F; Bataille R
The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells.
European journal of immunology 2000;30(3):803-9.
2000: Harousseau J L; Witz B; Lioure B; Hunault-Berger M; Desablens B; Delain M; Guilhot F; Le Prise P Y; Abgrall J F; Deconinck E; Guyotat D; Vilque J P; Casassus P; Tournilhac O; Audhuy B; Solary E
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):780-7.
2000: Yakoub-Agha I; Moreau P; Leyvraz S; Berthou C; Payen C; Dumontet C; Grosbois B; Beris P; Duguet C; Attal M; Harousseau J L; Facon T;
Thalidomide in patients with advanced multiple myeloma.
The hematology journal : the official journal of the European Haematology Association / EHA 2000;1(3):186-9.
1999: Derenne S; Amiot M; Barillé S; Collette M; Robillard N; Berthaud P; Harousseau J L; Bataille R
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1999;14(12):2048-56.
1999: Puthier D; Derenne S; Barillé S; Moreau P; Harousseau J L; Bataille R; Amiot M
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.
British journal of haematology 1999;107(2):392-5.
1999: Barillé S; Bataille R; Rapp M J; Harousseau J L; Amiot M
Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(10):5723-8.
1999: Thabard W; Barillé S; Collette M; Harousseau J L; Rapp M J; Bataille R; Amiot M
Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2693-7.
1999: Ifrah N; Witz F; Jouet J P; François S; Lamy T; Linassier C; Pignon B; Berthou C; Guyotat D; Cahn J Y; Harousseau J L
Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group.
Cancer 1999;86(8):1496-505.
1999: Bouabdallah R; Lefrère F; Rose C; Chaïbi P; Harousseau J L; Vernant J P; Castaigne S; Bauduer F; Zini J M; Coso D; Varet B; Robert J; Fenaux P
A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(10):1491-6.
1999: Avet-Loiseau H; Li J Y; Morineau N; Facon T; Brigaudeau C; Harousseau J L; Grosbois B; Bataille R
Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.
Blood 1999;94(8):2583-9.
1999: Avet-Loiseau H; Godon C; Li J Y; Daviet A; Mellerin M P; Talmant P; Harousseau J L; Bataille R
Amplification of the 11q23 region in acute myeloid leukemia.
Genes, chromosomes & cancer 1999;26(2):166-70.
1999: Avet-Loiseau H; Facon T; Daviet A; Godon C; Rapp M J; Harousseau J L; Grosbois B; Bataille R
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.
Cancer research 1999;59(18):4546-50.
1999: Avet-Loiseau H; Li J Y; Godon C; Morineau N; Daviet A; Harousseau J L; Facon T; Bataille R
P53 deletion is not a frequent event in multiple myeloma.
British journal of haematology 1999;106(3):717-9.
1999: Decaudin D; Lepage E; Brousse N; Brice P; Harousseau J L; Belhadj K; Tilly H; Michaux L; Chèze S; Coiffier B; Solal-Céligny P
Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2499-505.
1999: Barillé S; Thabard W; Robillard N; Moreau P; Pineau D; Harousseau J L; Bataille R; Amiot M
CD130 rather than CD126 expression is associated with disease activity in multiple myeloma.
British journal of haematology 1999;106(2):532-5.
1999: Facon T; Harousseau J L; Maloisel F; Attal M; Odriozola J; Alegre A; Schroyens W; Hulin C; Schots R; Marin P; Guilhot F; Granena A; De Waele M; Pigneux A; Méresse V; Clark P; Reiffers J
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
Blood 1999;94(4):1218-25.
1999: Jego G; Robillard N; Puthier D; Amiot M; Accard F; Pineau D; Harousseau J L; Bataille R; Pellat-Deceunynck C
Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.
Blood 1999;94(2):701-12.
1999: Moreau P; Milpied N; Mahé B; Juge-Morineau N; Rapp M J; Bataille R; Harousseau J L
Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma.
Bone marrow transplantation 1999;23(10):1003-6.
1999: Le Gouill S L; Morineau N; Miégeville M; Milpied N; Harousseau J L; Moreau P
[Pseudallescheria boydii osteoarthritis in a patient with acute lymphoblastic leukemia: a case report]
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 1999;20(5):434-8.
1999: Li J Y; Gaillard F; Moreau A; Harousseau J L; Laboisse C; Milpied N; Bataille R; Avet-Loiseau H
Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization.
The American journal of pathology 1999;154(5):1449-52.
1999: Milpied N; Coste-Burel M; Accard F; Moreau A; Moreau P; Garand R; Harousseau J L
Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation.
Bone marrow transplantation 1999;23(6):629-30.
1999: Pellat-Deceunynck C; Jego G; Harousseau J L; Vié H; Bataille R
Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(3):705-9.
1999: Moreau P; Huynh A; Facon T; Bouilly I; Sotto J J; Legros L; Milpied N; Attal M; Bataille R; Harousseau J L
Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Français du Myélome (IFM)
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(3):490-1.
1999: Puthier D; Pellat-Deceunynck C; Barillé S; Robillard N; Rapp M J; Juge-Morineau N; Harousseau J L; Bataille R; Amiot M
Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(2):289-94.
1999: Avet-Loiseau H; Brigaudeau C; Morineau N; Talmant P; Laï J L; Daviet A; Li J Y; Praloran V; Rapp M J; Harousseau J L; Facon T; Bataille R
High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization.
Genes, chromosomes & cancer 1999;24(1):9-15.
1998: Harousseau J L
[Methods for evaluating biological response modifiers]
Bulletin du cancer 1998;85(12):993-6.
1998: Avet-Loiseau H; Li J Y; Facon T; Brigaudeau C; Morineau N; Maloisel F; Rapp M J; Talmant P; Trimoreau F; Jaccard A; Harousseau J L; Bataille R
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
Cancer research 1998;58(24):5640-5.
1998: Pellat-Deceunynck C; Barillé S; Jego G; Puthier D; Robillard N; Pineau D; Rapp M J; Harousseau J L; Amiot M; Bataille R
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(12):1977-82.
1998: Milpied N; Gaillard F; Moreau P; Mahé B; Souchet J; Rapp M J; Bulabois C E; Morineau N; Harousseau J L
High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience.
Bone marrow transplantation 1998;22(7):645-50.
1998: Classe J M; Mahé M; Moreau P; Rapp M J; Maisonneuve H; Lemevel A; Bourdin S; Harousseau J L; Cuillière J C
Ovarian transposition by laparoscopy before radiotherapy in the treatment of Hodgkin's disease.
Cancer 1998;83(7):1420-4.
1998: Avet-Loiseau H; Garand R; Gaillard F; Daviet A; Mellerin M P; Robillard N; Bouyge I; Arcot S; Batzer M; Talmant P; Harousseau J L; Milpied N; Bataille R
Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia.
Genes, chromosomes & cancer 1998;23(2):175-82.
1998: Moreau P; Milpied N; Rapp M J; Moreau A; Bourdin S; Mahe M A; Dupas B; Le Tortorec S; Hamidou M; Maisoneuve H; Mahe B; Bulabois C E; Morineau N; Jardel H; Harousseau J L
Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: long-term follow-up in 35 cases.
Leukemia & lymphoma 1998;30(3-4):313-24.
1998: Moreau P; Milpied N; Voillat L; Colombat P; Mahé B; Rapp M J; Moreau A; Dupas B; Bulabois C E; Juge-Morineau N; Harousseau J L
Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Bone marrow transplantation 1998;21(12):1193-6.
1998: Moreau P; Leblond V; Bourquelot P; Facon T; Huynh A; Caillot D; Hermine O; Attal M; Hamidou M; Nedellec G; Ferrant A; Audhuy B; Bataille R; Milpied N; Harousseau J L
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.
British journal of haematology 1998;101(4):766-9.
1998: Robillard N; Jego G; Pellat-Deceunynck C; Pineau D; Puthier D; Mellerin M P; Barillé S; Rapp M J; Harousseau J L; Amiot M; Bataille R
CD28, a marker associated with tumoral expansion in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1521-6.
1998: Leblond V; Ben-Othman T; Deconinck E; Taksin A L; Harousseau J L; Delgado M A; Delmer A; Maloisel F; Mariette X; Morel P; Clauvel J P; Duboisset P; Entezam S; Hermine O; Merlet M; Yakoub-Agha I; Guibon O; Caspard H; Fort N
Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2060-4.
1998: Moreau P; Fleury J; Brice P; Colombat P; Bouabdallah R; Lioure B; Voillat L; Casasnovas O; François S; Sadoun A; Lamy T; Lotz J P; Munck J N; Divine M; Fermé C; Pény A M; Fruchart C; Oriol P; Ojeda M; Reman O; Milpied N; Gisselbrecht C; Legros M; Harousseau J L
Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry.
Bone marrow transplantation 1998;21(8):787-93.
1998: Mahé M A; Bourdin S; Le Mevel A; Moreau P; Moreau A; Hamidou M; Gaillard F; Rapp M J; Milpied N; Harousseau J L
Long-term results of total abdominopelvic irradiation in non-Hodgkin's lymphomas after failure of chemotherapy.
International journal of radiation oncology, biology, physics 1998;41(1):117-21.
1998: Witz F; Sadoun A; Perrin M C; Berthou C; Brière J; Cahn J Y; Lioure B; Witz B; François S; Desablens B; Pignon B; Le Prisé P Y; Audhuy B; Caillot D; Casassus P; Delain M; Christian B; Tellier Z; Polin V; Hurteloup P; Harousseau J L
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Blood 1998;91(8):2722-30.
1998: Andrieu J M; Jais J P; Colonna P; Desablens B; Brière J; François S; Harousseau J L; Casassus P; Lemevel A; Le Prisé P Y; Ghandour C; Guilhot F; Lejeune F
Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(2):195-203.
1997: Hermouet S; Niaussat A E; Briec A; Pineau D; Robillard N; Bataille R; Milpied N; Harousseau J L; Mahé B
Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products.
Hematology and cell therapy 1997;39(6):317-25.
1997: Paszek-Vigier M; Talmant P; Méchinaud F; Garand R; Harousseau J L; Bataille R; Avet-Loiseau H
Comparative genomic hybridization is a powerful tool, complementary to cytogenetics, to identify chromosomal abnormalities in childhood acute lymphoblastic leukaemia.
British journal of haematology 1997;99(3):589-96.
1997: Harousseau J L; Cahn J Y; Pignon B; Witz F; Milpied N; Delain M; Lioure B; Lamy T; Desablens B; Guilhot F; Caillot D; Abgrall J F; Francois S; Briere J; Guyotat D; Casassus P; Audhuy B; Tellier Z; Hurteloup P; Herve P
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Blood 1997;90(8):2978-86.
1997: Barillé S; Akhoundi C; Collette M; Mellerin M P; Rapp M J; Harousseau J L; Bataille R; Amiot M
Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells.
Blood 1997;90(4):1649-55.
1997: Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau J L; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall J F; Tanzer J
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
The New England journal of medicine 1997;337(4):223-9.
1997: Ringdén O; Labopin M; Gluckman E; Hows J M; Bradley B A; Kolb H J; Fouillard L; Jacobsen N; Vernant J P; Witz F; Harousseau J L; Gorin N C
Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study.
Bone marrow transplantation 1997;19(10):963-8.
1997: Jourdan E; Maraninchi D; Reiffers J; Gluckman E; Rio B; Jouet J P; Michallet M; Molina L; Archimbaud E; Harousseau J L; Ifrah N; Attal M; Guilhot F; Kuentz M; Guyotat D; Pico J L; Dauriac C; Legros M; Dreyfus F; Bordigoni P; Leblond V; Gratecos N; Varet B; Auzanneau C; Blaise D
Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).
Bone marrow transplantation 1997;19(9):875-81.
1997: Avet-Loiseau H; Vigier M; Moreau A; Mellerin M P; Gaillard F; Harousseau J L; Bataille R; Milpied N
Comparative genomic hybridization detects genomic abnormalities in 80% of follicular lymphomas.
British journal of haematology 1997;97(1):119-22.
1997: Moreau P; Fiere D; Bezwoda W R; Facon T; Attal M; Laporte J P; Colombat P; Haak H L; Monconduit M; Lockhorst H; Girault D; Harousseau J L
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):660-6.
1997: Juge-Morineau N; Harousseau J L; Amiot M; Bataille R
The retinoblastoma susceptibility gene RB-1 in multiple myeloma.
Leukemia & lymphoma 1997;24(3-4):229-37.
1996: Puthier D; Bataille R; Barillé S; Mellerin M P; Harousseau J L; Ponzio A; Robillard N; Wijdenes J; Amiot M
Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone.
Blood 1996;88(12):4659-66.
1996: Moreau P; Kergueris M F; Milpied N; Le Tortorec S; Mahé B; Bulabois C E; Rapp M J; Larousse C; Bataille R; Harousseau J L
A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity.
British journal of haematology 1996;95(3):527-30.
1996: Avet-Loiseau H; Devilder M C; Garand R; Bouyge I; Rapp M J; Milpied N; Harousseau J L; Moisan J P; Bataille R
13q14 deletions are not primary events in B-cell chronic lymphocytic leukemia: a study of 100 patients using fluorescence in situ hybridization.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1673-7.
1996: Harousseau J L; Pignon B; Witz F; Polin V; Tellier Z; Hurteloup P; Cahn J Y
Treatment of acute myeloblastic leukemia in adults. The GOELAM experience.
Hematology and cell therapy 1996;38(5):381-91.
1996: Moreau P; Méchinaud F; Mahé B; Le Tortorec S; Rapp M J; Maisonneuve H; Harousseau J L; Milpied N
Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma.
Bone marrow transplantation 1996;18(3):665-7.
1996: Pignon B; Witz F; Desablens B; Leprise P Y; Francois S; Linassier C; Berthou C; Caillot D; Lioure B; Cahn J Y; Casassus P; Sadoun A; Audhuy B; Guyotat D; Briere J; Vilque J P; Baranger L; Polin V; Berthaud P; Hurteloup P; Herve P; Harousseau J L
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group.
British journal of haematology 1996;94(2):333-41.
1996: Solary E; Witz B; Caillot D; Moreau P; Desablens B; Cahn J Y; Sadoun A; Pignon B; Berthou C; Maloisel F; Guyotat D; Casassus P; Ifrah N; Lamy Y; Audhuy B; Colombat P; Harousseau J L
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.
Blood 1996;88(4):1198-205.
1996: Colonna P; Jais J P; Desablens B; Harousseau J L; Brière J; Boasson M; Lemevel A; Casassus P; Le Prisé P Y; Guilhot F; Ghandour C; Lejeune F; Andrieu J M
Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1928-35.
1996: Guilhot F; Guerci A; Fiere D; Harousseau J L; Maloisel F; Bouabdallah R; Guyotat D; Rochant H; Najman A; Nicolini F; Colombat P; Abgrall J F; Ifrah N; Brière J; Bauters F; Navarro M; Morice P; Bordessoule D; Vilque J P; Desablens B; Tertian G; Blanc M; Chastang C; Tanzer J
The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group.
Bone marrow transplantation 1996;17 Suppl 3():S29-31.
1996: Solal-Céligny P; Brice P; Brousse N; Caspard H; Bastion Y; Haïoun C; Bosly A; Tilly H; Bordessoule D; Sebban C; Harousseau J L; Morel P; Dupas B; Plassart F; Vasile N; Fort N; Leporrier M
Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):514-9.
1996: Mahé B; Milpied N; Hermouet S; Robillard N; Moreau P; Letortorec S; Rapp M J; Bataille R; Harousseau J L
G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma.
British journal of haematology 1996;92(2):263-8.
1995: Mahé B; Gaillard F; Labadie F; Papin S; Letortorec S; Moreau P; Harousseau J L; Milpied N
Occurrence of a T cell lymphoma in a patient with chronic myeloid leukemia treated with alpha interferon.
Leukemia & lymphoma 1995;19(5-6):515-7.
1995: Juge-Morineau N; Mellerin M P; Francois S; Rapp M J; Harousseau J L; Amiot M; Bataille R
High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells.
British journal of haematology 1995;91(3):664-7.
1995: Cumin I; Mechinaud-Lacroix F; Avet-Loiseau H; Fischer A; Harousseau J L
[Neonatal acute leukemia: apropos of 7 cases]
Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie 1995;2(11):1060-6.
1995: Harousseau J L; Wu D
The use of GM-CSF and G-CSF in the treatment of acute leukemias.
Leukemia & lymphoma 1995;18(5-6):405-12.
1995: Pellat-Deceunynck C; Barillé S; Puthier D; Rapp M J; Harousseau J L; Bataille R; Amiot M
Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.
Cancer research 1995;55(16):3647-53.
1995: Mahé B; Moreau A; Moreau P; Le Tortorec S; Harousseau J L; Milpied N
High dose radiochemotherapy followed by autologous stem cell transplantation in four patients with multiple lymphomatous polyposis.
Cancer 1995;75(11):2742-6.
1995: Jourdan E; Maraninchi D; Reiffers J; Archimbaud E; Michallet M; Harousseau J L; Ifrah N; Rio B; Guyotat D; Guilhot F
Allogeneic bone marrow transplantation remains an efficient consolidation for adults with acute myeloid leukemia even when performed very soon after diagnosis (< 100 days). The SFGM (Société Française de Greffe de Moelle.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):1068-71.
1994: Avet-Loiseau H; Mechinaud-Lacroix F; Cohen J Y; Harousseau J L
Probable disseminated cerebral aspergillosis: recovery with medical treatment.
Nouvelle revue française d'hématologie 1994;36(6):419-22.
1994: Moreau P; Le Tortorec S; Mahé B; Legros L; Milpied N; Harousseau J L
Administration of granulocyte colony-stimulating factor from day 7 after autologous bone marrow transplantation: effects on neutropenia and duration of hospitalization.
Nouvelle revue française d'hématologie 1994;36(6):455-8.
1994: Moreau P; LeTortorec S; Mahé M A; Mahé B; Moreau A; Bourdin S; Bulabois C E; Bureau B; Harousseau J L; Milpied N
Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma.
Bone marrow transplantation 1994;14(5):775-8.
1994: Wu D P; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp M J; Bourdin S; Mahe J M; Harousseau J L
Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Bone marrow transplantation 1994;14(5):751-7.
1994: Mahé B; Moreau P; Bonnemain B; Letortorec S; Menegali D; Bourdin S; De Lajartre D; Harousseau J L
Isolated Richter's syndrome of the brain: two recent cases.
Nouvelle revue française d'hématologie 1994;36(5):383-5.
1994: Mahe B; Moreau P; Le Tortorec S; Hourmant M; Harousseau J L; Milpied N
Autologous bone marrow transplantation for cyclosporin-related lymphoma in a renal transplant patient.
Bone marrow transplantation 1994;14(4):645-6.
1994: Pellat-Deceunynck C; Bataille R; Robillard N; Harousseau J L; Rapp M J; Juge-Morineau N; Wijdenes J; Amiot M
Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
Blood 1994;84(8):2597-603.
1993: Quesnel B; Kantarjian H; Bjergaard J P; Brault P; Estey E; Lai J L; Tilly H; Stoppa A M; Archimbaud E; Harousseau J L
Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(12):2370-9.
1993: Moreau P; Zahar J R; Milpied N; Baron O; Mahé B; Wu D; Germaud P; Despins P; Delajartre A Y; Harousseau J L
Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection.
Cancer 1993;72(11):3223-6.
1993: Moreau P; Milpied N; Mechinaud-Lacroix F; Mahe B; Rapp M J; Le Tortorec S; Bourdin S; Dupas B; Harousseau J L
Early intensive therapy with autotransplantation for high-risk Hodgkin's disease.
Leukemia & lymphoma 1993;12(1-2):51-8.
1993: Harousseau J L; Pignon B; Cahn J Y
[Comparison between bone marrow autograft and intensive chemotherapy as treatment for maintenance of complete remission in acute myeloblastic leukemia in the adult. GOELAM Group]
Nouvelle revue française d'hématologie 1993;35(3):197-8.
1993: Harousseau J L
Is intensive treatment beneficial to elderly patients with ANLL?
Hematological oncology 1993;11 Suppl 1():4-8.
1992: Detourmignies L; Castaigne S; Stoppa A M; Harousseau J L; Sadoun A; Janvier M; Demory J L; Sanz M; Berger R; Bauters F
Therapy-related acute promyelocytic leukemia: a report on 16 cases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(9):1430-5.
1992: Harousseau J L; Milpied N; Laporte J P; Collombat P; Facon T; Tigaud J D; Casassus P; Guilhot F; Ifrah N; Gandhour C
Double-intensive therapy in high-risk multiple myeloma.
Blood 1992;79(11):2827-33.
1992: Avet-Loiseau H; Mechinaud-Lacroix F; Harousseau J L
[Ataxia telangiectasia]
Archives françaises de pédiatrie 1992;49(3):205-10.
1992: Harousseau J L; Pignon B; Dufour P; Ifrah N; Solary E; Abgrall J F; Milpied N; Desablens B; Guyotat D; Herve P
Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():120-3.
1991: Harousseau J L; Milpied N; Briere J; Desablens B; Leprise P Y; Ifrah N; Gandhour B; Casassus P
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(8):1432-7.
1991: Moreau P; Talmant P; Milpied N; Garand R; Lefranc G; Harousseau J L
Trisomy 4 associated with acute lymphocytic leukaemia.
British journal of haematology 1991;78(4):576.
1991: Harousseau J L; Milpied N; Briere J; Desablens B; Leprise P Y; Ifrah N; Gandhour B; Casassus P
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Seminars in hematology 1991;28(3 Suppl 4):80-3.
1991: Harousseau J L; Milpied N; Jouet J P; Colombat P; Guilhot F; Laporte J P; Ifrah N; Gandhour C; Casassus P
Intensive therapy for high grade multiple myeloma (MM).
Bone marrow transplantation 1991;7 Suppl 2():28.
1990: Praloran V; Dobo I; Garand R; Klausman M; Naud M F; Milpied N; Harousseau J L
Collagen gel cultures for detection of spared hematopoietic progenitors in Asta Z 7557 purged human marrows.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(4):282-6.
1990: Lepage E; Sebban C; Gisselbrecht C; Coiffier B; Harousseau J L; Bryon P A; Boiron M
Treatment of low-grade non-Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial.
Hematological oncology 1990;8(1):31-9.
1990: Harousseau J L; Milpied N; Briere J; Desablens B; Le Prise P Y; Ifrah N; Gandhour C; Casassus P
Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.
Haematology and blood transfusion 1990;33():299-303.
1990: Harousseau J L; Milpied N; Brière J; Desablens B; Ghandour C
Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
Nouvelle revue française d'hématologie 1990;32(4):227-30.
1989: Desablens B; Tourani J M; Casassus P; Brière J; Harousseau J L; Lemevel A; Ifrah N; Le Prise P Y; Gandhour C; Guilhot F
[Treatment of localized forms of Hodgkin's disease with 3 courses of chemotherapy (ABVD-MP) in combination with wide focal and prophylactic lumbo-splenic radiotherapy. The POF 81/12 protocol]
Presse médicale (Paris, France : 1983) 1989;18(39):1917-21.
1989: Praloran V; Klausman M; Naud M F; Harousseau J L
Blood erythroid progenitors (CFU-E and BFU-E) in acute lymphoblastic leukemias.
Blut 1989;58(2):75-8.
1989: Harousseau J L; Rigal-Huguet F; Hurteloup P; Guy H; Milpied N; Pris J
Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent.
European journal of haematology 1989;42(2):182-5.
1989: Fière D; Marty M; Solal-Celigny P; Harousseau J L; Gorin N C; Desablens B; Brière J; David B; Bordessoule D; Hayat M
[Intensive induction and early consolidation of acute lymphoid leukemia in the adult. A pilot study of feasibility and long-term development]
Presse médicale (Paris, France : 1983) 1989;18(5):221-3.
1989: Harousseau J L; Reiffers J; Hurteloup P; Milpied N; Guy H; Rigal-Huguet F; Facon T; Dufour P; Ifrah N
Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(1):45-9.
1987: Harousseau J L; Hurteloup P; Reiffers J; Rigal-Huguet F; Hayat M; Dufour P; Le Prise P Y; Monconduit M; Jaubert J; Carcassonne Y
Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.
Cancer treatment reports 1987;71(10):991-2.
1987: Robert J; Rigal-Huguet F; Harousseau J L; Pris J; Huet S; Reiffers J; Hurteloup P; Tamassia V
Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
Leukemia research 1987;11(11):961-4.
1987: Collado S; Marty M; Daniel M T; Harousseau J L; Bordessoule D; Extra J M; Degos L; Schaisson G; Boiron M
[Improved results in the treatment of acute monoblastic leukemia: analysis of 91 patients treated in the 01 AM 81 protocol]
Nouvelle revue française d'hématologie 1987;29(4):215-20.
1987: Marty M; Lepage E; Guy H; Bordessoule D; Desablens B; Harousseau J L; Guilhot F; Leverger G; Schaison G; Boiron M
Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study.
Haematology and blood transfusion 1987;30():50-6.
1985: Cariou R; Harousseau J L; André M J; Talmant P; Bray B; Garand R
[Chromosome 3 abnormalities with dysmegakaryocytopoiesis in in subacute transformation in chronic myeloid leukemia]
Nouvelle revue française d'hématologie 1985;27(1):23-6.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jean-Luc Harousseau

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jean-Luc Harousseau (preview)

All Publications